Heroin Rehab Cost in Pennsylvania: Treatment, IV Complications, 2026 Pricing
Heroin rehab in Pennsylvania costs $19,000 to $55,000 for a 30-day inpatient program without insurance, or $7,000 to $20,000 out-of-pocket with PPO insurance. Medical detox runs 10 to 14 days because most Pennsylvania heroin is both fentanyl AND xylazine contaminated (DEA 2024, Prevention Point Philadelphia drug checking) — Philadelphia specifically has among the nation’s highest xylazine detection rates in the country at 90%+ of fentanyl samples. IV-use medical complications (endocarditis, hepatitis C, HIV, xylazine wounds) frequently exceed the treatment bill itself. PA Medicaid covers comprehensive heroin treatment plus curative hepatitis C at $0 for 3.5 million enrollees; Prevention Point Philadelphia (the nation’s oldest SSP, established 1991) provides community-based harm reduction including specialized wound care.
Heroin use disorder in Pennsylvania in 2026 is really fentanyl + xylazine era opioid use disorder with an IV-use dimension that’s particularly severe in Philadelphia due to the xylazine wound epidemic. The supply is contaminated; medical complications are extensive and include xylazine-specific necrotic wounds; clinical protocols have evolved accordingly. This guide combines PA’s 2015–2024 policy infrastructure (Medicaid expansion, COE model, SCA system, Act 106 parity, Opioid Settlement Fund) with heroin-specific clinical protocols and the IV-use medical cost layer.
Pennsylvania Heroin Reality: Fentanyl + Xylazine Contaminated
DEA 2024 National Drug Threat Assessment data indicate more than 80% of U.S. heroin samples contain fentanyl. Philadelphia-specific drug checking by Prevention Point Philadelphia and the Philadelphia Department of Public Health finds xylazine in 90%+ of fentanyl samples — dramatically higher than other major cities.
Practically, most “heroin” users in Pennsylvania (particularly in Philadelphia) are effectively using fentanyl-xylazine mixtures.
Clinical Impact
- Longer detox — 10–14 days for fentanyl-xylazine-contaminated heroin
- Bernese induction preferred at PA academic centers
- Alpha-agonist withdrawal management for xylazine component
- Specialized wound care for xylazine necrotic ulcers
- Long-acting MAT (Brixadi weekly, Sublocade monthly)
- Multiple naloxone doses (4–8 mg) for fentanyl overdose
- Infection screening — MRSA, osteomyelitis
Geographic Variation in PA Heroin Supply
- Philadelphia / Kensington: Extreme xylazine contamination, epicenter of crisis
- Pittsburgh metro: Fentanyl + xylazine rising
- Lehigh Valley (Allentown, Bethlehem, Easton): Fentanyl-contaminated heroin
- Harrisburg / Central PA: Fentanyl + rising xylazine
- Scranton / Wilkes-Barre: Rural heroin + fentanyl + xylazine
- Rural PA / Northern Tier: Fentanyl-heroin with access challenges
For fentanyl-specific mechanics, see fentanyl rehab cost in Pennsylvania.
Why Pennsylvania Is Different for Heroin Treatment
1. Philadelphia Xylazine Wound Epidemic
Philadelphia has been the epicenter of the xylazine crisis since 2019–2020. Clinical protocols for xylazine-specific wound care were largely developed in Philadelphia hospitals.
2. Prevention Point Philadelphia — Nation’s Oldest SSP
Established 1991. Provides sterile syringes, naloxone, fentanyl/xylazine test strips, specialized wound care, hep C screening, HIV testing, MAT connection.
3. Centers of Excellence (COE) Integrated Care
PA’s 45+ COEs integrate heroin treatment with MAT + primary care + wound care + hep C treatment + HIV care + behavioral health — a national model for complex IV-heroin patient care.
4. Medicaid Expansion (2015) — 3.5M Enrollees
Covers full continuum including hep C cure at $0.
5. PA Medicaid Hepatitis C Cure Coverage
Removed earlier restrictions (sobriety requirements, fibrosis staging). $0 for eligible enrollees.
6. Single County Authority (SCA) System
47 SCAs serve all 67 counties. Free/sliding-scale for uninsured.
7. Authorized SSPs in Philadelphia and Pittsburgh
More established than many states. Critical access points for IV heroin users.
8. PA Opioid Settlement Fund ($1.07B+)
15% to Philadelphia given disproportionate burden — supports wound care, harm reduction, COE expansion.
9. Major Academic Medical Centers
Penn, Temple, Jefferson, UPMC, Allegheny Health Network, Einstein, Geisinger, Penn State Health — national leaders.
For full Pennsylvania regulatory context, see rehab cost in Pennsylvania. For heroin-specific clinical treatment nationally, see heroin rehab cost.
Heroin Rehab Cost in PA: 2026 Breakdown
| Level of Care | Duration | Without Insurance | With PPO |
|---|---|---|---|
| Medical detox (fentanyl + xylazine contaminated) | 10–14 days | $3,500 – $12,600 | $1,400 – $6,300 |
| Inpatient residential (standard) | 30 days | $19,000 – $28,000 | $7,000 – $14,000 |
| Inpatient residential (mid-tier) | 30 days | $28,000 – $42,000 | $12,000 – $20,000 |
| Main Line / Philly luxury | 30 days | $42,000 – $80,000+ | Capped at OOP max |
| Partial hospitalization (PHP) | 4–6 weeks | $5,000 – $16,000 | Capped at OOP max |
| Intensive outpatient (IOP) | 8–12 weeks | $4,000 – $12,000 | Capped at OOP max |
| MAT ongoing | 12–24+ months | $250 – $1,800/month | $25 – $350/month |
| Hepatitis C DAA cure (if IV user) | 8–12 weeks | $24,000 – $94,000 | $0 – $500 copay |
| Xylazine wound care (if applicable) | Variable | $2,000 – $25,000+ per episode | Medical benefit |
PA Medicaid covers all of the above — including hep C cure + xylazine wound care — at $0 for eligible enrollees.
IV-Use Medical Complications: The Hidden Cost Driver
IV heroin use produces medical complications that frequently exceed the rehab bill. Pennsylvania has an additional complication category — xylazine necrotic wounds — that’s particularly severe in Philadelphia.
| Complication | Typical Treatment Cost | Coverage |
|---|---|---|
| Endocarditis (heart valve infection) | $50,000 – $500,000+ per episode | Medical benefit — OOP max applies |
| Hepatitis C treatment (curative DAAs) | $24,000 – $94,000 per course | Medical benefit, PA Medicaid $0 |
| HIV treatment (lifetime) | $400,000 – $700,000 | Medical benefit + ADAP support |
| Xylazine necrotic wound care | $2,000 – $25,000+ per episode | Medical benefit |
| Soft tissue infections / abscesses | $5,000 – $50,000 per hospitalization | Medical benefit |
| Osteomyelitis (bone infection) | $50,000 – $200,000+ | Medical benefit |
| Sepsis requiring ICU | $40,000 – $200,000+ | Medical benefit |
Insurance context: Medical claims apply to medical deductible/OOP max.
PA Medicaid context: All covered at $0 for eligible enrollees.
PA Medicaid Hepatitis C Cure
Approximately 60–80% of long-term IV heroin users test positive for hepatitis C. PA Medicaid covers curative hep C treatment (DAAs — Mavyret, Harvoni, Epclusa, Sovaldi) at $0 for eligible enrollees.
Access Points
- PA DOH Hepatitis C Elimination Program — screening and treatment referral
- 45+ FQHCs statewide — free screening
- Prevention Point Philadelphia — hep C screening alongside harm reduction
- PA Academic Medical Centers (Penn, Temple, Jefferson, UPMC, AHN, Einstein, Geisinger) — comprehensive hep C care
- County health departments
How the Cure Works
- 8–12 week oral medication course
- 95–99% cure rate
- Restrictions (sobriety requirements, fibrosis staging) removed
- Covered at $0 for eligible Pennsylvanians
The cost-effectiveness is substantial: hep C cure prevents liver transplant ($500,000+) and liver cancer ($200,000+).
Xylazine Wound Care at PA Facilities
Given Philadelphia’s nation-leading xylazine rates (90%+ of fentanyl samples), PA facilities have developed advanced wound care protocols.
Clinical Components
- Wound assessment and staging
- Topical and systemic antibiotics
- Dressing changes (often multiple times daily)
- Surgical debridement for necrotic tissue
- Infection control — MRSA, osteomyelitis management
- Skin grafts for severe wounds (rare but occurs)
- Nutritional support for wound healing
- ID consult when needed
PA Facilities Specializing in Xylazine Wound Care
- Penn Medicine — academic leader in xylazine research and wound care
- Temple Health — Philadelphia safety net
- Jefferson Health — Philadelphia academic
- Einstein Medical Center — Kensington proximity
- UPMC — Pittsburgh academic
- Allegheny Health Network
- Prevention Point Philadelphia — community-based wound care
PA Harm Reduction Infrastructure
Prevention Point Philadelphia
Nation’s oldest SSP. Kensington-based. Services: sterile syringes, naloxone, fentanyl/xylazine test strips, hep C screening, HIV testing, specialized wound care, MAT connection, drug checking.
Prevention Point Pittsburgh
Long-established SSP in Pittsburgh. Similar services.
Other PA SSPs
Smaller programs in Lehigh Valley and other areas with varying legal frameworks. Less uniform than Florida’s 2019 statewide authorization.
PA DOH Naloxone Distribution
Project Free Naloxone — free naloxone through participating pharmacies (no prescription required) and community organizations.
HIV PrEP Access
Through county health departments, Penn Medicine, Philadelphia DPH, Planned Parenthood of PA.
PA Good Samaritan Law
PA’s Good Samaritan Law (Act 139 of 2014) provides protection for individuals calling emergency help during an overdose. Always call 911 — responders carry naloxone.
Heroin Withdrawal Timeline in Pennsylvania
| Hours Since Last Use | Clinical Picture | Setting |
|---|---|---|
| 6–12 | Anxiety, yawning, muscle aches, sweating, tearing | Baseline COWS; begin comfort meds |
| 24–48 | Peak (pure heroin) — muscle aches, nausea, vomiting | Initiate buprenorphine (pure heroin) |
| 48–72 | Fentanyl-contaminated: delayed/extended onset | Low-dose (Bernese) bup protocol |
| Day 3–7 | Xylazine withdrawal — sympathetic hyperactivity, insomnia | Alpha-agonists (clonidine, dexmedetomidine) |
| Day 7–14 | Xylazine component resolves | Transition to residential |
| Weeks 2–8 | PAWS | Outpatient MAT + therapy |
Heroin withdrawal is extremely uncomfortable but not medically dangerous. The post-detox 2-week window is the highest-risk overdose period due to tolerance loss.
MAT for Heroin Use Disorder in Pennsylvania
Seven FDA-approved opioid MAT approaches are covered by PA commercial plans and PA Medicaid.
| Medication | Mechanism | PA Self-Pay (Monthly) | PA Insured (Monthly) | PA Medicaid |
|---|---|---|---|---|
| Generic buprenorphine/naloxone | Partial agonist | $350 – $800 | $25 – $200 | $0 – $5 |
| Suboxone brand | Partial agonist | $400 – $600 | $25 – $150 | $0 – $5 |
| Sublocade (monthly) | Long-acting bup | $1,600 – $1,800 | $50 – $300 | $0 – $10 |
| Brixadi (weekly or monthly) | Long-acting bup — fentanyl-era preference | $600 – $1,800 | $50 – $350 | $0 – $10 |
| Methadone (OTPs) | Full agonist | $300 – $550 | $50 – $200 | $0 |
| Vivitrol (monthly injection) | Antagonist | $1,300 – $1,700 | $0 – $300 | $0 – $10 |
| Oral naltrexone | Antagonist | $50 – $150 | $10 – $50 | $0 – $3 |
Choosing MAT for PA Heroin Patients
- Generic buprenorphine: First-line; office-based; lowest cost
- Brixadi weekly: Strongly preferred for fentanyl-era patients
- Sublocade monthly: For stable patients with compliance concerns
- Methadone (OTPs): 80+ PA OTPs; severe OUD or prior bup failure
- Vivitrol: Requires 7–14 days opioid-free
ED-Initiated Buprenorphine Bridges at PA Hospitals
Major PA hospitals have operational ED-bup bridge programs:
- Penn Medicine — multiple Philadelphia hospitals
- Temple University Hospital
- Jefferson Health
- Einstein Medical Center
- UPMC Mercy / UPMC Presbyterian (Pittsburgh)
- Allegheny General Hospital (Pittsburgh)
- Geisinger Medical Center
- Penn State Hershey
- Lehigh Valley Hospital-Cedar Crest
- St. Luke’s University Health
Ask in the ED: “Is there an ED-initiated buprenorphine bridge program?”
How Do Pennsylvanians Afford Heroin Rehab?
1. PA Medicaid (3.5 Million Enrollees)
Full continuum + hep C cure + xylazine wound care at $0 through managed care plans.
2. Private Commercial Insurance
Highmark BCBS, Independence Blue Cross, UPMC Health Plan, Geisinger, Aetna, UHC. Capped at $7,000–$9,500 OOP max.
3. Single County Authorities (SCAs)
47 SCAs, all 67 counties. Call 1-800-662-4357.
4. Gaudenzia Nonprofit
30+ PA locations.
5. PA Opioid Settlement Fund Programs
Counties + state + Philadelphia (15% allocation).
6. Prevention Point Philadelphia + Other SSPs
Harm reduction + MAT referral.
7. Centers of Excellence (COE)
Integrated care.
8. Faith-Based and Sliding-Scale
Salvation Army ARCs, Teen Challenge PA, 45+ FQHCs.
Choosing a PA Heroin Rehab
Verification questions before admission:
- Is the facility DDAP-licensed? Verify via Treatment Atlas
- Is the facility accredited?
- Is the facility in-network for my plan?
- Do you offer low-dose (Bernese) buprenorphine induction?
- Is Brixadi weekly on formulary?
- Do you have xylazine wound care capacity?
- Do you connect to hepatitis C screening and treatment?
- Are you a Center of Excellence (COE)?
- What’s the MAT continuation plan at discharge?
- What’s my deductible and OOP max, and what’s met year-to-date?
Pennsylvania Heroin Resources
State and City Resources
- PA Get Help Now Helpline: 1-800-662-4357 (24/7)
- PA DDAP: pa.gov/agencies/ddap
- PA DOH Hepatitis C Elimination: pa.gov/agencies/health
- SAMHSA National Helpline: 1-800-662-4357
- 988 Suicide & Crisis Lifeline: 988
Harm Reduction
- Prevention Point Philadelphia — nation’s oldest SSP (Kensington)
- Prevention Point Pittsburgh
- PA DOH Project Free Naloxone — free naloxone
- PA participating pharmacies — no-prescription naloxone
- Philadelphia DPH Drug Checking Program
Major Counties
- Philadelphia: 215-685-6440 (DBHIDS)
- Allegheny (Pittsburgh): 412-350-4457
- Montgomery / Bucks / Chester / Delaware: 211
- Lehigh Valley: 211
- Dauphin (Harrisburg): 211
Success Rate Reality
Heroin use disorder recovery rates depend on MAT continuation:
- With MAT for 12+ months: 40–60% sustained recovery
- Without MAT: 10–30%
- MAT reduces overdose death risk by ~50% (NIDA)
- Treatment retention 2–4x higher on MAT
Recovery is a chronic-disease process. Most heroin patients need multiple treatment episodes.
Final Thoughts
Pennsylvania heroin treatment in 2026 is fentanyl + xylazine era treatment with an especially severe IV-use medical complication dimension, particularly in Philadelphia. The policy infrastructure (Medicaid expansion + COE model + SCA system + Act 106 + $1.07B Opioid Settlement Fund + Prevention Point Philadelphia) is among the strongest in the nation — but the Kensington crisis remains severe.
Five steps:
- Check PA Medicaid eligibility — 3.5M qualify for $0 coverage including hep C + wound care
- If uninsured: Call 1-800-662-4357 for SCA referral
- Ask about Bernese induction + Brixadi + xylazine wound care at admitting facility
- Ask about Centers of Excellence (COE) for integrated care
- Use ED-bup bridge if in an ED after overdose
For broader context, see rehab cost in Pennsylvania, heroin rehab cost, fentanyl rehab cost in Pennsylvania, opioid rehab cost in Pennsylvania, and medical detox cost.
Sources
- Philadelphia Department of Public Health. “Drug Supply Surveillance.” 2023–2024.
- Pennsylvania Department of Health. “Drug Overdose Data.” 2023.
- Prevention Point Philadelphia. “Services and Impact Reports.” 2024.
- Drug Enforcement Administration. “National Drug Threat Assessment.” 2024.
- Pennsylvania DDAP. “Centers of Excellence and Treatment Atlas.” 2024.
- PA Opioid Misuse and Addiction Abatement Trust. 2024.
- American Association for the Study of Liver Diseases (AASLD) and IDSA. “Hepatitis C Guidance.” 2024.
- Randhawa PA, et al. “Buprenorphine Low-Dose Induction (Bernese Method).” Journal of Addiction Medicine. 2024.
- D’Onofrio G, et al. “Emergency Department–Initiated Buprenorphine.” JAMA. 2023.
- Friedman JR, et al. “Xylazine contamination of the opioid supply.” 2023.
- National Institute on Drug Abuse. “Heroin Research Report.” 2024.
- American Society of Addiction Medicine. “Clinical Practice Guideline for the Treatment of Opioid Use Disorder.” 2020.
- Pennsylvania Act 139 of 2014. “Good Samaritan Law.”
- Pennsylvania Act 106 (2024). “Mental Health and Substance Use Disorder Parity.”
- SAMHSA Behavioral Health Treatment Services Locator. 2025. https://findtreatment.samhsa.gov/
Heroin Treatment in Pennsylvania — Is Your Plan Enough?
Even with insurance, many people discover their plan doesn't cover residential treatment at the level they need. A broker who specializes in behavioral health coverage can review your situation and find a plan that works.
Call 1-866-454-9577Free Consultation · No Obligation
Prodest Insurance Group is a licensed, independent health insurance brokerage. Calling the number above connects you with a licensed insurance agent, not a treatment facility. Insurance placement is a separate service from treatment referral.
Frequently Asked Questions
How much does heroin rehab cost in Pennsylvania?
Heroin rehab in Pennsylvania costs $19,000–$55,000 for 30 days of inpatient treatment without insurance, or $7,000–$20,000 out-of-pocket with PPO insurance (capped at the 2026 OOP max of $7,000–$9,500). Medical detox adds $3,500–$12,600 (10–14 days — longer because most PA heroin is fentanyl + xylazine contaminated, particularly in Philadelphia where xylazine reaches 90%+ of fentanyl samples). PA Medicaid (3.5 million enrollees) covers the full heroin treatment continuum at $0 — including curative hepatitis C treatment (DAA medications $24,000–$94,000 per course) frequently needed by IV heroin users. Ongoing MAT runs $25–$350/month insured; $250–$1,800 self-pay. For uninsured residents, 47 Single County Authorities (SCAs) provide free or sliding-scale treatment.
Is heroin contaminated with fentanyl and xylazine in Pennsylvania?
Yes — and Pennsylvania (particularly Philadelphia) has among the nation's highest contamination rates. DEA 2024 data and Prevention Point Philadelphia drug checking show: (1) fentanyl in 80%+ of PA heroin samples, following the national trend; (2) xylazine in 90%+ of Philadelphia fentanyl samples — dramatically higher than other major cities (NY 31%, NJ 29%, CA 15%, FL/TX 10–15%); (3) xylazine presence in statewide PA samples is also elevated compared to most states. Practically, most 'heroin' users in Pennsylvania — especially in Philadelphia — are effectively using fentanyl-xylazine mixtures. This changes clinical treatment: detox typically runs 10–14 days; low-dose (Bernese) buprenorphine induction is preferred; alpha-agonists (clonidine, dexmedetomidine) manage xylazine withdrawal; specialized wound care addresses xylazine necrotic ulcers; long-acting MAT (Brixadi weekly, Sublocade monthly) is often recommended.
How long does heroin detox take in Pennsylvania?
Heroin detox in Pennsylvania typically takes 10–14 days — longer than the 5–7 days historically seen for pure heroin and longer than the 7–10 days for fentanyl-only contamination, because most PA heroin has both fentanyl AND xylazine contamination. Withdrawal symptoms begin 6–12 hours after last use, peak on days 2–5 for fentanyl-contaminated, and extend through days 10–14 for xylazine component. Post-acute withdrawal symptoms (PAWS — mood changes, sleep disruption, cravings) persist weeks to months. Many Pennsylvania academic medical centers (Penn Medicine, Temple Health, Jefferson, UPMC, Allegheny Health Network, Geisinger, Einstein) use low-dose (Bernese) buprenorphine induction specifically because traditional COWS-threshold induction causes precipitated withdrawal in fentanyl-contaminated patients. For xylazine component, alpha-agonists (clonidine, dexmedetomidine) manage withdrawal; specialized wound care addresses injection-site necrotic ulcers.
Does Pennsylvania Medicaid cover heroin rehab?
Yes, comprehensively. PA Medicaid (Medical Assistance) covers the full heroin use disorder treatment continuum at $0 cost for 3.5 million enrollees through managed care plans (AmeriHealth Caritas, Highmark Wholecare, UPMC for You, Keystone First, Geisinger Health Plan): medical detox (up to 14+ days including xylazine-specific protocols), inpatient residential, PHP, IOP, outpatient, all FDA-approved MAT medications (Brixadi weekly, Sublocade monthly, Suboxone, methadone through OTPs, Vivitrol, oral naltrexone), curative hepatitis C treatment (DAAs — Mavyret, Harvoni, Epclusa, Sovaldi), and Centers of Excellence (COE) integrated care including wound care. PA Medicaid removed earlier hep C restrictions (sobriety requirements, fibrosis staging) that limited access for active drug users. Apply at [compass.state.pa.us](https://www.compass.state.pa.us/) or 1-866-550-4355.
What are the hidden medical costs of IV heroin use in Pennsylvania?
IV heroin use produces medical complications that frequently exceed the rehab bill itself — and Pennsylvania (particularly Philadelphia) has an additional cost category due to xylazine wound complications. Typical PA treatment costs: endocarditis (heart valve infection) $50,000–$500,000+ per episode; hepatitis C curative DAAs $24,000–$94,000 per course; HIV treatment lifetime $400,000–$700,000; xylazine necrotic wound care (sometimes requiring surgical debridement or skin grafts) $2,000–$25,000+ per episode; soft tissue infections / abscesses $5,000–$50,000 per hospitalization; osteomyelitis (bone infection) $50,000–$200,000+; sepsis requiring ICU $40,000–$200,000+. These are medical claims, not behavioral health — they apply to your medical deductible and out-of-pocket max. PA Medicaid covers all of these at $0 for eligible enrollees, including curative hepatitis C and xylazine wound care. Prevention Point Philadelphia provides community-based wound care and hep C screening.
Does Pennsylvania Medicaid cover hepatitis C treatment for heroin users?
Yes. PA Medicaid covers curative hepatitis C treatment (direct-acting antivirals — Mavyret, Harvoni, Epclusa, Sovaldi) at $0 for eligible enrollees. The typical course runs 8–12 weeks with cure rates of 95–99%. PA Medicaid removed earlier restrictions (sobriety requirements, fibrosis staging) that historically limited access for active drug users, aligning with CDC and AASLD guidelines. Access points: PA Department of Health hep C elimination program; 45+ FQHCs statewide offering free screening; Prevention Point Philadelphia (nation's oldest SSP) with hep C screening; academic medical centers (Penn Medicine, Temple, Jefferson, UPMC, Allegheny Health Network) with comprehensive hep C care; county health departments. The cost-effectiveness is substantial: hep C cure prevents liver transplant ($500,000+) and liver cancer ($200,000+) in IV heroin users.
What is Prevention Point Philadelphia?
Prevention Point Philadelphia (PPP) is the nation's oldest syringe service program (SSP), established in 1991 and operating in the Kensington neighborhood at the epicenter of the Philadelphia fentanyl-xylazine-heroin crisis. PPP provides services particularly relevant to IV heroin users: sterile syringes, naloxone distribution, fentanyl and xylazine test strips, hepatitis C screening, HIV testing, specialized wound care for xylazine necrotic ulcers, connection to MAT and treatment, HIV PrEP referral, peer support, and drug checking in partnership with Philadelphia DPH. PPP has reversed thousands of overdoses and connects thousands annually to treatment. Its wound care program is a national model — Kensington's xylazine crisis required development of community-based necrotic wound treatment. PPP operates under Pennsylvania's authorization framework for SSPs (more established in Philadelphia and Allegheny County than some other PA counties).
Does Pennsylvania have authorized syringe service programs?
Pennsylvania's legal framework for syringe service programs (SSPs) is complex but functional — more established than Texas (no state-level authorization) though less uniform than Florida (2019 statewide authorization). Major authorized PA SSPs: (1) Prevention Point Philadelphia (nation's oldest, 1991, Kensington); (2) Prevention Point Pittsburgh; (3) smaller SSPs in Lehigh Valley and other areas with varying legal authority. Under Pennsylvania law, SSPs operate through local public health authority — Philadelphia and Allegheny County (Pittsburgh) have the most established programs. For IV heroin users, SSPs provide: sterile syringes, naloxone, fentanyl/xylazine test strips, hep C screening, wound care, HIV testing, MAT connection. These access points are critical for reducing HIV/hep C transmission and connecting active users to treatment when they're ready. Other PA counties have more limited SSP access — contact your local SCA or DOH for harm reduction resources.
What is Bernese low-dose buprenorphine induction?
Bernese low-dose (micro-dose) buprenorphine induction is a protocol that starts buprenorphine at very low doses (0.5 mg) while the patient is still using a full opioid agonist like fentanyl-contaminated heroin, then gradually titrates up over 5–7 days before discontinuing the full agonist. This avoids precipitated withdrawal — a dangerous complication that occurs when traditional COWS-threshold induction is attempted in patients with high fentanyl tissue load. Because fentanyl is fat-soluble and accumulates in body tissues, fentanyl-contaminated heroin users often experience precipitated withdrawal with traditional induction. Bernese protocols are now preferred at Pennsylvania academic medical centers (Penn Medicine, Temple Health, Jefferson Health, UPMC, Allegheny Health Network, Einstein Medical Center, Geisinger Medical Center, Penn State Hershey, Lehigh Valley Health Network) and a growing number of community residential providers.